---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-019884"
form_type: "8-K/A"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:19:18.168879+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biofrontera to acquire US Ameluz/RhodoLED rights; royalty 12-15%, 10% equity stake

## Summary
- Upfront EUR 2,593,750 payment due June 30, 2025; condition to raise $8.5M preferred equity by same date.
- Royalty on US net sales: 12% up to $65M revenue, 15% above; minimum 80,000 tubes/year penalty clause.
- Sellers receive preferred stock convertible to 10% of fully diluted Biofrontera Inc. common equity.
- Sellers get 1-2 board seats as long as they hold preferred stock; term sheet void if conditions unmet.
- Buyer assumes all US supply costs and legal defense; stockholder vote required for conversion rights.

## SEC filing metadata
- accession: 0001641172-25-019884
- form_type: 8-K/A
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000164117225019884/0001641172-25-019884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000164117225019884/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-019884
- JSON: https://secwatch.observer/filing/0001641172-25-019884.json
- Plain text: https://secwatch.observer/filing/0001641172-25-019884.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.